ELEVEN BIOTHERAPEUTICS, INC. (EBIO) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
On November 14, 2016, Eleven Biotherapeutics, Inc. (the Company)
announced its financial results for the quarter ended September
30, 2016. The full text of the press release issued in connection
with the announcement is furnished as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by
reference.
announced its financial results for the quarter ended September
30, 2016. The full text of the press release issued in connection
with the announcement is furnished as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by
reference.
The information provided under this Form 8-K (including Exhibit
99.1) shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act) or
otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.
99.1) shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act) or
otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
|
(d)
|
Exhibits
|
The following exhibit relating to Item 2.02 shall be deemed to be
furnished, and not filed:
furnished, and not filed:
|
99.1
|
Press release issued by the Company on November 14,
2016 |
||
About ELEVEN BIOTHERAPEUTICS, INC. (EBIO)
